Zentalis Advances Azenosertib Trials with Pivotal Dose Selection and Phase 3 Initiation

Event summary

  • Zentalis selected 400mg QD 5:2 as the pivotal dose for azenosertib monotherapy in Cyclin E1-positive PROC based on DENALI Part 2a data.
  • First patient dosed in the ASPENOVA Phase 3 confirmatory trial for azenosertib in Cyclin E1-positive PROC.
  • DENALI Phase 2 topline readout expected by year-end 2026, potentially supporting accelerated approval.
  • Cash position of $211.8 million as of March 31, 2026, providing runway into late 2027.

The big picture

Zentalis is advancing its WEE1 inhibitor azenosertib through pivotal trials, targeting an unmet need in Cyclin E1-positive platinum-resistant ovarian cancer. The company's biomarker-driven approach and regulatory strategy aim to position azenosertib as a potential first-in-class therapy, while its cash runway supports key milestones into late 2027. The progress in DENALI and ASPENOVA trials underscores the company's focus on bringing a non-chemotherapy, oral treatment option to a significant portion of PROC patients.

What we're watching

Regulatory Pathway
Whether DENALI Part 2 data will support accelerated approval and how FDA feedback shapes the timeline.
Clinical Execution
The pace at which ASPENOVA Phase 3 trial enrolls and generates confirmatory data for full approval.
Pipeline Expansion
How early data from MUIR Part 2 and AACR presentations influence strategic decisions on combination therapies.